Clinical trial
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic…
NCT05768711 · Groupe Francophone des Myelodysplasies, Other · Active, not recruiting
Key facts
| NCT number | NCT05768711 |
|---|---|
| Title | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) |
| Official title | Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML) |
| Acronym | AVENHIR |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Collaborators | AbbVie Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Venetoclax |
| Enrollment | 44 |
| Start date | Oct 4, 2023 |
| Primary completion | Feb 1, 2026 |
| Completion | Oct 1, 2028 |
| First posted | Mar 14, 2023 |
| Last update posted | Dec 8, 2025 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: